JP2013522326A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522326A5
JP2013522326A5 JP2013500247A JP2013500247A JP2013522326A5 JP 2013522326 A5 JP2013522326 A5 JP 2013522326A5 JP 2013500247 A JP2013500247 A JP 2013500247A JP 2013500247 A JP2013500247 A JP 2013500247A JP 2013522326 A5 JP2013522326 A5 JP 2013522326A5
Authority
JP
Japan
Prior art keywords
subject
compound
prodrug
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522326A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029283 external-priority patent/WO2011116399A1/en
Publication of JP2013522326A publication Critical patent/JP2013522326A/ja
Publication of JP2013522326A5 publication Critical patent/JP2013522326A5/ja
Pending legal-status Critical Current

Links

JP2013500247A 2010-03-19 2011-03-21 がん幹細胞を標的とするための新規の方法 Pending JP2013522326A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US61/315,890 2010-03-19
US61/315,886 2010-03-19
US32581410P 2010-04-19 2010-04-19
US61/325,814 2010-04-19
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015179115A Division JP6246169B2 (ja) 2010-03-19 2015-09-11 がん幹細胞を標的とするための新規の方法

Publications (2)

Publication Number Publication Date
JP2013522326A JP2013522326A (ja) 2013-06-13
JP2013522326A5 true JP2013522326A5 (pt-PT) 2014-04-17

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500247A Pending JP2013522326A (ja) 2010-03-19 2011-03-21 がん幹細胞を標的とするための新規の方法

Country Status (16)

Country Link
US (2) US9730909B2 (pt-PT)
EP (1) EP2547205B1 (pt-PT)
JP (1) JP2013522326A (pt-PT)
CN (1) CN103025159A (pt-PT)
AU (1) AU2011227023B2 (pt-PT)
BR (1) BR112012023660B8 (pt-PT)
CA (2) CA2793527A1 (pt-PT)
DK (1) DK2547205T3 (pt-PT)
FI (1) FI2547205T3 (pt-PT)
HR (1) HRP20240658T1 (pt-PT)
LT (1) LT2547205T (pt-PT)
PL (1) PL2547205T3 (pt-PT)
RS (1) RS65536B1 (pt-PT)
RU (1) RU2591823C2 (pt-PT)
SI (1) SI2547205T1 (pt-PT)
WO (1) WO2011116399A1 (pt-PT)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
CA2959951A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
CN109867647A (zh) 2014-02-07 2019-06-11 北京强新生物科技有限公司 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐
DK3153508T3 (da) * 2014-06-09 2020-05-18 Kyoto Pharma Ind Naphthofuranderivater til anvendelse som anticancermidler
CA2983011A1 (en) 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
BR112017022281A2 (pt) 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
KR20180015195A (ko) 2015-06-03 2018-02-12 보스톤 바이오메디칼, 인크. 암의 치료에 사용하기 위한 암 줄기능 저해제 및 면역치료제를 포함하는 조성물
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EP3405189A1 (en) 2016-01-20 2018-11-28 Boston Biomedical, Inc. Methods for treating cancer
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
US10953369B2 (en) * 2018-03-08 2021-03-23 Georgia Tech Research Corporation Spirocentric compounds and polymers thereof
BR112021006898A2 (pt) 2018-10-12 2021-07-20 1Globe Biomedical Co., Ltd. nova solução de combinação para tratar câncer refratário à quimioterapia
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途
CN117350965A (zh) * 2023-10-07 2024-01-05 中国原子能科学研究院 对象内放射性微球的指标预估装置

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのstat3シグナル伝達の阻害
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
MXPA02000828A (es) 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1469733A4 (en) 2001-11-29 2008-07-23 Therakos Inc METHODS FOR PRETREATING A SUBJECT USING EXTRACORPOREAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS
DK1344533T3 (da) 2002-03-15 2007-01-08 Natimmune As Farmaceutiske præparater, der omfatter mannosebindende lectin
AU2003275056A1 (en) * 2002-09-17 2004-04-08 Arqule, Inc. Novel lapacho compounds and methods of use thereof
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
WO2005058829A1 (en) 2003-12-11 2005-06-30 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
US20060030536A1 (en) 2004-04-09 2006-02-09 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
US20060247318A1 (en) 2005-02-25 2006-11-02 Hui Song Small molecule inhibitors of STAT3 and the uses thereof
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
ES2533383T3 (es) 2006-03-31 2015-04-09 The Board Of Regents Of The University Of Texas System Fármacos anticancerosos biodisponibles por vía oral relacionados con ácido cafeico
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法
CN101854802B (zh) * 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
CA2959951A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells

Similar Documents

Publication Publication Date Title
JP2013522326A5 (pt-PT)
JP2013525444A5 (pt-PT)
JP2014507446A5 (pt-PT)
JP2013014622A5 (pt-PT)
JP2016501221A5 (pt-PT)
JP2012255026A5 (pt-PT)
JP2013509429A5 (pt-PT)
JP2016518337A5 (pt-PT)
JP2014508752A5 (pt-PT)
JP2010001302A5 (pt-PT)
JP2015536964A5 (pt-PT)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2011102304A5 (pt-PT)
JP2013542247A5 (pt-PT)
JP2015529234A5 (pt-PT)
JP2012193216A5 (pt-PT)
JP2015501783A5 (pt-PT)
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
JP2013509411A5 (pt-PT)
RU2017105353A (ru) Соединения
JP2014509653A5 (pt-PT)
JP2015516419A5 (pt-PT)
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
JP2014530818A5 (pt-PT)
JP2013544892A5 (pt-PT)